

- 20 Dasgupta B, Milbrandt J. *Proc Natl Acad Sci USA* 2007; **104**: 7217–7222.
- 21 Puissant A, Robert G, Fenouille N *et al.* *Cancer Res* 2010; **70**: 1042–1052.
- 22 Puissant A, Auberger P. *Autophagy* 2010; **6**: 655–657.

- 23 Aymard E, Barruche V, Naves T *et al.* *Exp Dermatol* 2011; **20**: 263–268.
- 24 Kang H T, Lee K B, Kim S Y *et al.* *PLoS ONE* 2011; **6**: e23367.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Appendix S1. Materials and methods.

Appendix S2. Figures.

DOI: 10.1111/exd.12177

www.wileyonlinelibrary.com/journal/EXD

Letter to the Editor

Role of *CPI-17* in restoring skin homeostasis in cutaneous field of cancerization: effects of topical application of a film-forming medical device containing photolyase and UV filters

Joan Anton Puig-Butillé^{1,2}, Josep Malvehy^{2,3}, Miriam Potrony^{1,2}, Carles Trullas⁴, Francisco Garcia-García^{5,6}, Joaquin Dopazo^{5,6,7} and Susana Puig^{2,3}

¹Melanoma Unit, Biochemistry and Molecular Genetics Service, Hospital Clinic of Barcelona, IDIBAPS, Barcelona, Spain; ²CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain; ³Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, IDIBAPS, Barcelona, Spain; ⁴ISDIN, Barcelona, Spain; ⁵Department of Bioinformatics, Centro de Investigación Príncipe Felipe, Valencia, Spain; ⁶Functional Genomics Node, National Institute of Bioinformatics, CIPF, Valencia, Spain; ⁷CIBER de Enfermedades Raras (CIBERER), Valencia, Spain
Correspondence: Susana Puig, MD, Consultant, Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Villarroel 170. 08036 Barcelona, Spain, Tel.: +34-93-2275400 ext 2893, Fax: +34-93-2275438, e-mails: susipuig@gmail.com; spuig@clinic.ub.es

Abstract: Cutaneous field of cancerization (CFC) is caused in part by the carcinogenic effect of the cyclobutane pyrimidine dimers CPD and 6-4 photoproducts (6-4PPs). Photoreactivation is carried out by photolyases which specifically recognize and repair both photoproducts. The study evaluates the molecular effects of topical application of a film-forming medical device containing photolyase and UV filters on the precancerous field in AK from seven patients. Skin improvement after treatment was confirmed in all patients by histopathological and molecular assessment. A gene set analysis showed that skin recovery was associated with biological processes involved in tissue

homeostasis and cell maintenance. The CFC response was associated with over-expression of the *CPI-17* gene, and a dependence on the initial expression level was observed ($P = 0.001$). Low *CPI-17* levels were directly associated with pro-inflammatory genes such as *TNF* ($P = 0.012$) and *IL-1B* ($P = 0.07$). Our results suggest a role for *CPI-17* in restoring skin homeostasis in CFC lesions.

Key words: actinic keratoses – *CPI-17* – cutaneous field of cancerization – expression array – *PPP1R14A*

Accepted for publication 20 May 2013

Background

Cutaneous field of cancerization (CFC) is associated with genomic alterations due to the carcinogenic effect of sun exposure (1) and comprises actinic keratoses (AKs) and squamous cell carcinomas (SCCs) (2). UV radiation, particularly UVB, promotes the production of cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts (6-4PPs) which subsequently interfere with biological processes that are critical for cell viability (3). The nucleotide excision repair (NER) system is employed by mammal cells to remove UV-induced DNA damage (4). However, whereas 6-4PPs are efficiently recognized and removed by the NER system, CPDs recognition and removal is poor (5,6). Many organisms have an additional repair mechanism named photoreactivation, which is carried out by photolyases which specifically recognize and repair either CPDs or 6-4PPs (7). The potential of DNA photolyases in skin cancer prevention has been increasingly recognized. Beneficial effects after transferring a CPD photolyase into mammals have been obtained in transgenic mice (8). Transgenic expression of

photolyases showed a 40% increase in CPD lesion repair, improved resistance against UV-induced effects suppressing the formation of skin carcinomas. Furthermore, topical application of liposome formulations with CPD photolyases onto human skin provides protection against UVB-induced damage (9).

Questions addressed

We explored the molecular effects of topical application of Eryfotona[®] AK-NMSC (Eryf-AK; ISDIN, Barcelona, Spain), a film-forming medical device containing Repairsomes[®] (photolyase in liposomes and UV filters), in patients with CFC.

Experimental design

For experimental design and procedures see Data S1.

Results

Three of seven patients with CFC (AK Pretreatment biopsies) presented a complete histological clearance, one patient presented histological clearance in more than 80% of the sample, and three additional cases presented partial histological improvement associated with inflammation. Based upon the histopathology




Figure 1. Values of relative quantification of selected genes and markers by subtype of patients (fast responders versus partial responders) and time of treatment (prior pretreatment or posttreatment): (a) Values of relative quantification of *CPI-17* ($2^{-\Delta\Delta C_t}$). **P*-values <0.05, ***P*-values <0.001. (b) Values of relative quantification of *WDR72* ($2^{-\Delta\Delta C_t}$). *P*-values pretreatment lesion = 0.631; *P*-value posttreatment lesion = 0.211. (c) Values of relative quantification of *TNF α* ($2^{-\Delta\Delta C_t}$). **P*-values <0.05; *P*-value posttreatment lesion = 0.447. (d) Values of relative quantification of *IL-1 β* ($2^{-\Delta\Delta C_t}$). **P*-values <0.05; *P*-value pretreatment lesion = 0.070.

assessment after Eryf-AK treatment, the subjects were classified as fast responders (FR) versus slow-partial responders (PR) (Table S1).

The differential gene expression analysis of CFC pretreatment versus posttreatment assessment failed to detect deregulated genes after correction for multiple testing. However, over-expressions of *CPI-17* gene (2.8-fold increase, *P* = 0.039) and *WDR72* gene (1.9-fold increase, *P* = 0.040) were detected in FR subgroup. *CPI-17* expression differences between FR and PR subgroups were confirmed by RT-PCR (*P* = 0.001) (Figure 1a). In contrast, no

significant differences (*P* = 0.211) were observed for *WDR72* (Figure 1b). Initial *CPI-17* levels were higher in FR than PR patients (*P* = 0.045; Figure 1a).

Pathological conditions such as inflammation modulate *CPI-17* expression (10). Thus, expression of *TNF* and *IL-1B* cytokines were evaluated. FR showed lower expression levels of *TNF* (*P* = 0.012) and *IL-1B* (*P* = 0.07) after Eryf-AK (Figure 1c,d). Posttreatment PR lesions still showed a high *IL-1B* expression level (*P* = 0.038).

Gene set analysis identified 150 biological functions (*P* < 0.005; Table S2) associated with CFC, which were classified in four major biological clusters: 'generation of reactive oxygen species', 'mechanisms involved in DNA repair', 'cell division process' and 'lipids'.

Sixty six processes were associated with Eryf-AK treatment (*P* < 0.005, Table S3), which were grouped as 'cell communication and signalling', 'cell adhesion' and 'tissue development'.

Gene set analysis according to treatment response identified 24 GOs over-expressed in FR subgroup mostly involved in cell response and homeostasis and 28 GO's associated with PR lesions which were related to inflammation and cytokine production, apoptosis and lipid metabolic processes (Table 1).

Conclusions

We identified biological processes associated with CFC such as ROS production and DNA damage repair processes that may be induced in part by CPDs and/or lipid metabolism. Lipid content changes are important in AK and BCC (11). After treatment, we found over-expression of fundamental processes related to tissue reconstitution (cell communication, signalling and adhesion).

Based on treatment response, treated PR biopsies showed an over-expression of apoptotic process, lipid metabolism, cytokine production and inflammation which are directly related to AK. Inflammation is important for AK maintenance which is abolished by the topical use of diclofenac combined with hyaluronic acid through a selective inhibition of COX2 (12–14). The histopathological evaluation showed the presence of AK in at least 20% of the biopsy specimen from PR patients. In treated FR subgroup, we observed an improvement in cell homeostasis and adhesion

Table 1. Gene ontology terms detected by gene set analysis in posttreatment biopsies by response subgroup

| Response to treatment ¹ | Gene Ontology terms (ID and <i>P</i> -value) ² |
|------------------------------------|--|
| Fast responders (FR) | Cell-cell signalling (0007267, <i>P</i> = 3.02E-06); Embryonic development (0009790, <i>P</i> = 1.15E-05); Cell development (0048468, <i>P</i> = 1.46E-05); Secretion (0046903, <i>P</i> = 2.10E-05); Regulation of secretion (0051046, <i>P</i> = 1.22E-04); Muscle contraction (0006936, <i>P</i> = 1.87E-04); Chemical homeostasis (0048878, <i>P</i> = 2.44E-04); Anterior/posterior pattern formation (0009952, <i>P</i> = 3.05E-04); Cellular homeostasis (0019725, <i>P</i> = 4.93E-04); Embryonic development ending in birth or egg hatching (0009792, <i>P</i> = 6.73E-04); Chordate embryonic development (0043009, <i>P</i> = 1.8E-03); Homeostatic process (0042592, <i>P</i> = 1.30E-03); Ion homeostasis (0050801, <i>P</i> = 1.53E-03); Secretion by cell (0032940, <i>P</i> = 1.53E-03); Response to steroid hormone stimulus (0048545, <i>P</i> = 2.00E-03); Cell fate commitment (0045165, <i>P</i> = 2.19E-03); Response to hypoxia (0001666, <i>P</i> = 2.22E-03); Cellular chemical homeostasis (0055082, <i>P</i> = 2.23E-03); Regulation of blood vessel size (0050880, <i>P</i> = 2.76E-03); Smooth muscle contraction (0006939, <i>P</i> = 3.26E-03); Response to inorganic substance (0010035, <i>P</i> = 4.09E-03); Response to hormone stimulus (0009725, <i>P</i> = 4.37E-03); Neurological system process (0050877, <i>P</i> = 3.08E-02); Cell morphogenesis (0000902, <i>P</i> = 1.17E+00) |
| Partial responders (PR) | Organic acid metabolic process (0006082, <i>P</i> = 3.35E-18); Carboxylic acid metabolic process (0019752, <i>P</i> = 3.35E-18); Lipid metabolic process (0006629, <i>P</i> = 1.28E-13); Cellular lipid metabolic process (0044255, <i>P</i> = 8.13E-13); Lipid biosynthetic process (0008610, <i>P</i> = 2.09E-09); Regulation of immune response (0050776, <i>P</i> = 1.09E-08); Steroid metabolic process (0008202, <i>P</i> = 7.70E-08); Regulation of interleukin-6 production (0032675, <i>P</i> = 2.07E-07); Regulation of cytokine production (0001817, <i>P</i> = 2.07E-07); Positive regulation of immune response (0050778, <i>P</i> = 2.81E-06); Carbohydrate metabolic process (0005975, <i>P</i> = 3.67E-05); Leucocyte migration (0050900, <i>P</i> = 4.62E-05); Neutral lipid metabolic process (0006638, <i>P</i> = 1.65E-04); Glycerol ether metabolic process (0006662, <i>P</i> = 1.65E-04); Regulation of lipid metabolic process (0019216, <i>P</i> = 1.80E-04); Positive regulation of cytokine production (0001819, <i>P</i> = 1.83E-04); Response to drug (0042493, <i>P</i> = 3.12E-04); cellular carbohydrate metabolic process (0044262, <i>P</i> = 3.61E-04); Locomotory behaviour (0007626, <i>P</i> = 3.91E-04); Lipid storage (0019915, <i>P</i> = 8.60E-04); Response to organic substance (0010033, <i>P</i> = 2.62E-03); Interleukin-12 production (0032615, <i>P</i> = 2.95E-03); Apoptosis (0006915, <i>P</i> = 2.96E-03); Negative regulation of cytokine production (0001818, <i>P</i> = 3.01E-03); Programmed cell death (0012501, <i>P</i> = 3.68E-03); Response to molecule of bacterial origin (0002237, <i>P</i> = 3.96E-03); Regulation of programmed cell death (0043067, <i>P</i> = 4.06E-03); Amine metabolic process (0009308, <i>P</i> = 4.74E-03) |

¹Patients were classified as fast responders and partial responders based on the histopathology assessment after Eryf-AK treatment (see Table S1).

²The ID numbers and the *P*-values are indicated for each GO.

which correlates with the improvement in histopathological measures (Puig et al. 2012; submitted for publication).

CPI-17 over-expression was associated with normal phenotype recovery. *CPI-17* is one of the major Ser/Thr phosphatase isoforms, and its activation suppresses the MYPT1-PP1 δ activity resulting in muscle contraction (10). *CIP-17* expression is detected in multiple cell types (15–17) involved in several processes (16,18). MYTP1 inhibition results in more prominent focal adhesions and absence of cell migration (19). *CPI-17* is directly associated with focal adhesion kinases (20) and located at focal adhesions in fibroblasts and keratinocytes (21). MYPT1-PP1 δ complex can also regulate the dephosphorylation of retinoblastoma protein (pRb) (22) which shows a deregulated activation in AK. We observed that inflammation modulates *CPI-17* expression in CFC. Thus, processes such as DNA damage or ROS production may cause *CPI-17* down-deregulation, which could lead to uncontrolled MYPT1-PP1 δ activity. Deregulated phosphatase activity in CFC may affect cell motility, cell adhesion and cell cycle control mediated by pRb.

References

- Park W S, Lee H K, Lee J Y et al. *Hum Pathol* 1996; **27**: 1180–1184.
- Cockerell C J. *J Am Acad Dermatol* 2000; **42**: 11–17.
- Vink A A, Roza L. *J Photochem Photobiol, B* 2001; **65**: 101–104.
- Hoeijmakers J H. *Nature* 2001; **411**: 366–374.
- Bohr V A, Smith C A, Okumoto D S et al. *Cell* 1985; **40**: 359–369.
- Mitchell D L. *Photochem Photobiol* 1988; **48**: 51–57.
- Essen L O, Klar T. *Cell Mol Life Sci* 2006; **63**: 1266–1277.
- Jans J, Schul W, Sert Y G et al. *Curr Biol* 2005; **15**: 105–115.
- Stege H, Roza L, Vink A A et al. *Proc Natl Acad Sci U S A* 2000; **97**: 1790–1795.
- Eto M. *J Biol Chem* 2009; **284**: 35273–35277.
- Vural P, Canbaz M, Sekcuki D et al. *Int J Dermatol* 1999; **38**: 439–442.
- Maltusch A, Rowert-Huber J, Matthias C et al. *J Dtsch Dermatol Ges* 2011; **9**: 1011–1017.
- Fecker L F, Stockfleth E, Braun F K et al. *J Invest Dermatol* 2010; **130**: 2098–2109.
- Rodust P M, Fecker L F, Stockfleth E et al. *Exp Dermatol* 2012; **21**: 520–525.
- Eto M, Senba S, Morita F et al. *FEBS Lett* 1997; **410**: 356–360.
- Eto M, Bock R, Brautigan D L et al. *Neuron* 2002; **36**: 1145–1158.
- Woodsome T P, Eto M, Everett A et al. *J Physiol* 2001; **535**: 553–564.
- Jin H, Sperka T, Herrlich P et al. *Nature* 2006; **442**: 576–579.
- Xia D, Stull J T, Kamm K E. *Exp Cell Res* 2005; **304**: 506–517.
- Fresu M, Bianchi M, Parsons J T et al. *Biochem J* 2001; **358**: 407–414.
- Villa-Moruzzi E, Tognarini M, Cecchini G et al. *Cell Adhes Commun* 1998; **5**: 297–305.
- Kiss A, Lontay B, Becsi B et al. *Cell Signal* 2008; **20**: 2059–2070.

Acknowledgements

S.P and J.M designed the research study. S.P collected skin biopsies and obtained the clinical data. J.A.P.B performed the whole-genome expression arrays. M.P performed the RT-PCR. J.A.P.B, F.G.G and J.D analysed and interpreted the results; J.A.P.B wrote the paper. C.T reviewed the manuscript. The present project was partially funded by a grant from ISDIN. The research at the Melanoma Unit in Barcelona is partially funded by Grants from Fondo de Investigaciones Sanitarias (09/01393), Spain; by the CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain; by the AGAUR 2009 SGR 1337 of the Catalan Government, Spain. This work is also partly supported by grants BIO2008-04212 from the Spanish Ministry of Science and Innovation (MICINN) and PROMETEO/2010/001 from the GVA-FEDER.

Conflict of interests

The authors state no conflict of interests. The sponsors had no role in the design and conduct of the study and interpretation of data.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Data S1. Study design.

Table S1. Patient demographics and classification based on response to treatment.

Table S2. GO's biological processes overrepresented in CFC prior to Eryfotona AK-NMSC treatment.

Table S3. GO's biological processes overrepresented in lesional skin post Eryfotona AK-NMSC treatment.

DOI: 10.1111/exd.12182

www.wileyonlinelibrary.com/journal/EXD

Letter to the Editor

Pretreatment of epidermal growth factor promotes primary hair recovery via the dystrophic anagen pathway after chemotherapy-induced alopecia

Seung Hwan Paik^{1*}, Ji-Seon Yoon^{2,3*}, Hyeong Ho Ryu¹, Ji Yeon Lee^{2,3}, Chang Yup Shin³, Kyung Hyun Min⁴, Seong Jin Jo^{1,2,3}, Kyu Han Kim^{1,2,3} and Ohsang Kwon^{1,2,3}

¹Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea; ²Laboratory of Cutaneous Aging and Hair Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea; ³Institute of Human-Environment Interface Biology, Biomedical Research Center, Seoul National University, Seoul, Korea; ⁴Bio Research Laboratory, Life Science Research Institute, Daewoong Pharmaceutical Co., Ltd., Yongin, Korea

Correspondence: Ohsang Kwon, Department of Dermatology, Seoul National University College of Medicine, 101 Daehangno, Jongno-gu, Seoul 110-744, Korea, Tel.: +82-(2)-2072-2417, Fax: +82-(2)-742-7344, e-mail: oskwon@snu.ac.kr

*These authors contributed equally to this work.

Abstract: Epidermal growth factor (EGF) is not only a cell growth stimulant but also has a catagen-inducing effect. Because

chemotherapeutic agents primarily damage anagen hair follicles, it would be important to investigate whether catagen inducers have